Glenmark launches mounted dose mixture drug for diabetes in India


The corporate has launched the product beneath two model names — Remo V and Remozen V

Glenmark Prescribed drugs on Tuesday mentioned it has launched a fixed-dose mixture drug for the remedy of Sort 2 diabetes within the nation.

It has launched a fixed-dose mixture of Remogliflozin Etabonate and Vildagliptin in India for the administration of Sort 2 diabetes, the Mumbai-based firm mentioned in an announcement.

The drug comprises Remogliflozin (100 mg) and Vildagliptin (50 mg) in a fixed-dose and should be taken twice each day to enhance glycemic management in sufferers, it added.

The corporate has launched the product beneath two model names — Remo V and Remozen V — within the nation.

“Glenmark is the primary firm on this planet to launch Remogliflozin + Vildagliptin fixed-dose mixture and India is the primary nation to get entry to this FDC drug,” the drugmaker mentioned.

The corporate had acquired approval for the product from the DCGI in late November.

Whereas the common each day value of remedy of present manufacturers in the identical drug class is ₹78, Glenmark”s Remogliflozin-Vildagiptin mixture has been launched at ₹14 per pill, to be taken twice each day; which quantities to ₹28 because the per-day value of the remedy, Glenmark mentioned.

This value is 65% decrease than the opposite out there SGLT2 and DPP4 mixture medication out there, it added.

“We’re glad to introduce this progressive fixed-dose mixture, which is cutting-edge, extensively researched, and at an inexpensive value for sufferers within the nation,” Glenmark Group Vice President and Enterprise Head India Formulations Alok Malik mentioned.

Diabetes is a key space of focus for the corporate and the launch of this product will allow it to enhance entry to diabetes remedy by offering an efficient and inexpensive remedy choice to sufferers in India, he added.

Globally, SGLT2 inhibitors (Sodium-Glucose Co-Transporter Inhibitor) and DPP4 inhibitors (Dipeptidyl Peptidase four inhibitor) are rising as the popular remedy possibility for the administration of Sort 2 diabetes.

Based on the Worldwide Diabetes Federation, there have been round 77 million adults in India residing with diabetes as of 2019.

You might have reached your restrict totally free articles this month.

Subscription Advantages Embody

At the moment’s Paper

Discover mobile-friendly model of articles from the day’s newspaper in a single easy-to-read checklist.

Limitless Entry

Take pleasure in studying as many articles as you want with none limitations.

Personalised suggestions

A choose checklist of articles that match your pursuits and tastes.

Sooner pages

Transfer easily between articles as our pages load immediately.

Dashboard

A one-stop-shop for seeing the most recent updates, and managing your preferences.

Briefing

We temporary you on the most recent and most essential developments, 3 times a day.

Help High quality Journalism.

*Our Digital Subscription plans don’t at the moment embody the e-paper, crossword and print.

Leave a Reply

Your email address will not be published. Required fields are marked *